Claims for Patent: 6,165,470

Summary for Patent: 6,165,470

Title:	Albumin derivatives with therapeutic functions
Abstract:	Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.
Inventor(s):	Becquart; Jerome (Paris, FR), Fleer; Reinhard (Gif sur Yvette, FR), Hirel; Philippe (Paris, FR), Klatzmann; David (Paris, FR), Landais; Didier (Paris, FR), Mayaux; Jean-Fran.cedilla.ois (Fontenay aux Roses, FR), Yeh; Patrice (Paris, FR)
Assignee:	Rhone-Poulenc (Antony, FR)
Application Number:	09/004,319
Patent Claims:	1. A hybrid peptide comprising the V.sub.1 domain or V.sub.1 V.sub.2 domains of the CD4 receptor of a human immunodeficiency virus, wherein the N-terminal end of said domain or domains is covalently coupled to albumin or a derivative of albumin. 2. A hybrid peptide according to claim 1, wherein said hybrid peptide lacks one or more proteolytic cleavage sites between the V.sub.1 domain or V.sub.1 V.sub.2 domains of CD4 and albumin or a derivative of albumin. 3. A hybrid peptide according to claim 1, wherein said albumin is of human origin. 4. A hybrid peptide comprising the V.sub.1 domain or V.sub.1 V.sub.2 domains of the CD4 receptor of a human immunodeficiency virus, wherein said domain or domains are covalently coupled to albumin or a derivative of albumin, and a polypeptide region conferring a dimerization or polymerization function. 5. A hybrid peptide according to claim 1, wherein the covalent coupling comprises a peptide linkage. 6. A hybrid peptide according to any one of claims 1, 2, 3, 4, or 5 together with a pharmaceutically acceptable vehicle. 7. A hybrid peptide comprising the V.sub.1 domain or V.sub.1 V.sub.2 domains of the CD4 receptor of a human immunodeficiency virus, wherein said domain or domains are covalently coupled to albumin or a derivative of albumin and further comprising a leucine zipper domain. 8. A hybrid peptide comprising the V.sub.1 domain or V.sub.1 V.sub.2 domains of the CD4 receptor of a human immunodeficiency virus, wherein the N-terminal end of said domain or domains is covalently coupled to human albumin. 9. A hybrid peptide according to claim 8, wherein said hybrid peptide is a secretory peptide, which binds to an OKT4A antibody, a Leu3A antibody, and polyclonal anti-human serum albumin antibodies. 10. A hybrid peptide according to any one of claims 7, or 9 together with a pharmaceutically acceptable vehicle. 11. A hybrid peptide according to claim 1, further comprising a hinge region between the albumin or albumin derivative and the V.sub.1 domain or V.sub.1 V.sub.2 domains. 12. A hybrid peptide according to claim 8, further comprising a hinge region between the albumin and the V.sub.1 domain or V.sub.1 V.sub.2 domains. 13. A hybrid peptide according to claim 1, wherein the half-life of the hybrid peptide, which has been injected into a rabbit, is 34 hours .+-.4 hours. 14. A hybrid peptide according to claim 8 or claim 12, wherein the half-life of the hybrid peptide, which has been injected into a rabbit, is 34 hours .+-.4 hours. 15. A hybrid peptide according to claim 14, wherein said hybrid peptide is a secretory peptide, which binds to an OKT4A antibody, a Leu3A antibody, and polyclonal anti-human serum albumin antibodies.

Details for Patent 6,165,470

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2009-08-03
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2009-08-03
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2009-08-03
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2009-08-03